Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Sara Pellegrino - VP, IR & Public Relations Maria Fardis - CEO, President & Director Friedrich Finckenstein - Chief Medical Officer Michael Swartzburg - VP, Finance and Interim Principal Financial Officer & Principal Accounting Officer Conference Call Participants Peter Lawson - Barclays Bank Mara Goldstein - Mizuho Securities Mark Breidenbach - Oppenheimer Boris Peaker - Cowen and C ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other juris ...

Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer October 2020 Forward Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, filings with the Securities and Exchange Commission ("SEC") ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sara Pellegrino - Vice President Investor and Public Relations Maria Fardis - President and Chief Executive Officer Friedrich Finckenstein - Chief Medical Officer Michael Swartzburg - Vice President of Finance and Principal Accounting Officer Jim Ziegler - Head of Commercial Conference Call Participants Peter Lawson - Barclays Jim Birchenough - Wells Fargo Ben Burnett - Stifel Mara Gol ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other jurisdicti ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. U.S. and Europe), such as statements regarding the timing of initiation and completion of these trials; the timing of and our ability to successfully submit, obtain and maintain FDA or designation ("BTD" ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET Company Participants Sara Pellegrino - Vice President Investor & Public Relations Maria Fardis - President & Chief Executive Officer Friedrich Finckenstein - Chief Medical Officer Tim Morris - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Peter Lawson - Barclays Jim Birchenough - Wells Fargo Joe Catanzaro - Piper Sandler Madhu Kumar - Baird Boris Peaker - Cowen Mark Breidenbach ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other jurisdiction of (I.R.S. employer incorporation or organization) identification number) 999 Skyway Road, Suite 150, San Carlos, CA 94070 (Address of principal executive offices and zip code) (650) 260-7120 ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 | | | Name Of Each Exchange | | --- | --- | --- | | Title of Each Class | Trading Symbol(s) | On Which Registered | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from __________ to __________ Commis ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other juris ...